Skip to main content
SpringerLink
Log in

In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

All-trans retinoic acid (ATRA) is used in the treatment of acute promyelocytic leukemia. Because ATRA has effects (increase in apoptosis, suppression of bcl-2), it has also been used for the treatment of other French-American-British (FAB) subtypes of acute myelogenous leukemia (AML). To find out the in vivo and in vitro effects of ATRA in AML, we analyzed 37 patients with de novo AML. Twenty-seven patients received ATRA before remission-induction (RI) treatment (ATRA group). Results were compared to a control group (10 patients) that received induction without ATRA during the same time period. Bone marrow or peripheral blood samples were collected from all patients on d 0 and 4. The immunphenotype, myeloperoxidase (MPO), reaction and the efflux uptake of rhodamine 123 (Rh123) were analyzed on myeloblasts in these samples. In the myeloblasts from patients treated with ATRA, the uptake of Rh123 was increased significantly (p=0.026) from d 0 to d 4, and all other parameters remained unaltered. ATRA administration increased the complete remission (CR) rate (88%, 22/25 vs 55%, 5/9) significantly (p=0.042). Logistic regression analysis revealed that ATRA administration was the important factor in CR, among other potential factors including age, white blood count, bcl-2 expression, and the uptake and efflux of Rh123 (p=0.05). Estimated disease-free survival and overall survival were similar between these two groups (43% vs 37.5% and 51.2% vs 37.5%, respectively). In conclusion, ATRA treatment prior to RI treatment may improve the CR rate in patients with de novo AML, which seems to be related to its beneficial effect on multidrug resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bishop, J. F., Matthews, J. P., Young, G. A. R., Bradstock, K. and Lowenthal, R. M. (1998). Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia. A review and updated results from Australian Leukemia Study group. Leukemia Lymphoma 28:315–327.

    PubMed  CAS  Google Scholar 

  2. Heil, G., Hoelzer, D., Sanz, M. A. (1997). A randomised, double-blind, place-controlled, phase III study of filgrastrim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 90:4710–4718.

    PubMed  CAS  Google Scholar 

  3. Marie, J. P., Zhou, D. C., Gurbuxani, S., Legrand, O. and Zittoun, R. (1996). MDR1/P-glicoprotein in haematological neoplasms. Eur. J. Cancer 32A:1034–1038.

    Article  PubMed  CAS  Google Scholar 

  4. Hickman, J. A. (1996). Apoptosis and chemotherapy resistance. Eur. J. Cancer 32A:921–926.

    Article  PubMed  CAS  Google Scholar 

  5. Goldstein, L. J., Golski, H., Fojo, A. (1989). Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 81:116–124.

    Article  PubMed  CAS  Google Scholar 

  6. Musto, P., Melillo, L., Lombardi, G., et al. (1991). High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br. J. Haematol. 77:50–53.

    PubMed  CAS  Google Scholar 

  7. Sato, H., Gottesman, M. M., Goldstein, L. J., et al. (1990). Expression of the multidrug resistance gene in myeloid leukemias. Leukemia Res 14:11–21.

    Article  CAS  Google Scholar 

  8. Zhou, D. C., Marie, J. P., Suberville, A. M. and Zittoun, R. (1992). Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 6:879–885.

    PubMed  CAS  Google Scholar 

  9. Beksac, M., Akan, H., Koc, H., et al. (1992). P-glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporin A containing regimens. Med. Oncol. Tumor Pharmacol. 9:101–105.

    CAS  Google Scholar 

  10. Campos, L., Guyotat, D., Archimbaud, E. (1992). Clinical significance of multidrug resistance P-glicoprotein (P170) expression on acute nonlymphoblastic leukemia cells. Blood 79:473–476.

    PubMed  CAS  Google Scholar 

  11. Pirker, R., Wallner, J., Geissler K., et al. (1991). MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst. 83:708–713.

    Article  PubMed  CAS  Google Scholar 

  12. Marie, J. P., Faussat-Suberville, A. M., Zhou, D. and Zittoun, R. (1993). Daunorubicin uptake by leukemic cells: correlation with treatment outcome and mdr1 expression. Leukemia 7:825–831.

    PubMed  CAS  Google Scholar 

  13. Leith, C. P., Chen, I. M., Kopecky, K. J., et al. (1995). Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia (AML) by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR+/effluxcases. Blood 86:2329–2342.

    PubMed  CAS  Google Scholar 

  14. Sincock, P. M. and Ashman, L. K. (1997). Expression of c-Kit and functional drug efflux are correlated in de novo acute myeloid leukemia. Leukemia 11:1850–1857.

    Article  PubMed  CAS  Google Scholar 

  15. Martinez, A., San Miguel, J. F., Valverde, B., et al. (1997). Functional expression of MDR1 in acute myeloid leukemia: correlation with the clinical-biological, immunophenotypical, and prognostic disease characteristics. Ann. Hematol. 75:81–86.

    Article  PubMed  CAS  Google Scholar 

  16. Sonneveld, P. (1996). Reversal of multidrug resistance in acute myeloid leukemia and other hematological malignancies. Eur. J. Cancer 32A:1062–1069.

    Article  PubMed  CAS  Google Scholar 

  17. Reed, J. C. (1995). Bcl-2 family proteins and mechanisms of chemoresistance in lymphomas and leukemias. Adv. Leukemia Lymphoma 5:3–11.

    Google Scholar 

  18. Miyashita, T. and Reed, J. C. (1993). Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151–157.

    PubMed  CAS  Google Scholar 

  19. Campos, L., Sabido, O., Rouault, J. P. and Guyotat, D. (1994). Effects of bcl-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 84:595–600.

    PubMed  CAS  Google Scholar 

  20. Bradbury, D. A. and Russel, N. H. (1995). Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells. Br. J. Haematol. 91:374–379.

    PubMed  CAS  Google Scholar 

  21. Hu, Z., Yang, G. S., Li M., et al. (1995). Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia:involvement of free radicals. Leukemia 9:789–798.

    PubMed  CAS  Google Scholar 

  22. Hu, Z.-B., Minden, M. D. and McCulloch, E. A. (1995). Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells. Leukemia 9:1667–1673.

    PubMed  CAS  Google Scholar 

  23. Miyashita, T. and Reed, J. C. (1992). Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52:5407–5411.

    PubMed  CAS  Google Scholar 

  24. Kondo, S., Yin, D., Morimura, T. and Takeuichi, J. (1994). Bcl-2 gene prevents induction of apoptosis in L1210 murine leukemia cells by SN-38, a metabolite of the camphotecin deriative CPT-11. Int. J. Oncol. 4:649–654.

    CAS  Google Scholar 

  25. Campos, L., Rouault, J. P., Sabido, O., et al. (1993). High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091–3096.

    PubMed  CAS  Google Scholar 

  26. Karakas, T., Maurer, U., Weidmann, E., et al. (1998). High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol. 9:159–165.

    Article  PubMed  CAS  Google Scholar 

  27. Maung, Z. T., MacLean, E. R., Reid, M. M., et al. (1994). The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br. J. Haematol. 88:105–109.

    PubMed  CAS  Google Scholar 

  28. Campos, L., Oriol, P., Sabido, O. and Guyotat, D. (1997). Simultaneous expression of p-glicoprotein and bcl-2 in acute myeloid leukemia blast cells. Leukemia Lymphoma 27:119–125.

    PubMed  CAS  Google Scholar 

  29. Del Poeta, G., Del Poeta, G., Venditti, A., Aronica, G., et al. (1997). Simultaneous P-glycoprotein and bcl-2 overexpression identifies a subset of acute myeloid leukemia patients at worst prognosis. Blood 90:302a (abstract).

  30. Avvisatti, G., Lococo, F., DiVerio, D., et al. (1996). AIDA (all-trans-retinoic acid+idarubucin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Mailgne dell’Adulto (GIMEMA) pilot study. Blood 88:1390–1398.

    Google Scholar 

  31. Hu, Z.-B., Minden, M. D. and McCulloch, E. A. (1996). Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy. Leukemia 10:410–416.

    PubMed  CAS  Google Scholar 

  32. Zheng, A., Mantymaa, P., Saily, M., et al. (1999). An association between mitocondrial function and all-trans retinoic acid-induced apoptosis in acute myeloblastic leukemia cells. Br. J. Haematol. 105:215–224.

    Article  PubMed  CAS  Google Scholar 

  33. Tosi, P., Pellacani, A., Visani, G., et al. (1999). In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells. Eur. J. Haematol. 62:143–148.

    Article  PubMed  CAS  Google Scholar 

  34. Eck, K. M., Yuan, L., Duffy, L., et al. (1998). A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cells. Br. J. Cancer 77:2129–2137.

    PubMed  CAS  Google Scholar 

  35. Zou, C. P., Kurie, J. M., Lotan, D., et al. (1998). Higher potency of N-(4-hydroxyphenyl) retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin. Cancer Res. 4:1345–1355.

    PubMed  CAS  Google Scholar 

  36. Venditti, A., et al. (1995). All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of a poor prognosis acute myeloid leukemia. Leukemia 9:1121–1125.

    PubMed  CAS  Google Scholar 

  37. Estey, E. H., Thall, P., Pierce, S., et al. (1999). Randomised phase II trial of fludarabine+ara-c+idarubicin+/-all-trans retinoic acid (ATRA) +/-G-CSF in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93:2478–2484.

    PubMed  CAS  Google Scholar 

  38. Seiter, K., Feidman, E. J., Dorota Halicka, H., et al. (2000). Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukaemia. Br. J. Haematol. 108;40–47.

    Article  PubMed  CAS  Google Scholar 

  39. Karp, J., Kapoport, C., Sarkodee-Adoo, D., et al. (1999). Two-cycle tied sequential therapy (TST) of adult acute myelobenous leukemia (AML) plus all-trans retinioic acid (ATRA) priming:Early results of a phase II trial. Blood 94: 1338a (abstract).

    Google Scholar 

  40. Young, I. T. (1977). Proof without prejudice use of the Kolmogrov-Smirnov test for the analysis of histograms from flow systems and other sources. J. Histochem. Cytochem. 25:935–941.

    PubMed  CAS  Google Scholar 

  41. Beksac, M., Arslan, O, Koc, H., et al. (1998). Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukemia. Med. Oncol. 15:183–190.

    PubMed  CAS  Google Scholar 

  42. Yang, G. S., Minden, M. D. and McCulloch, E. A. (1994). Regulation by retinoic acid and hydrocortisone of the antracycline sensitivity of blast cells of acute myeloblastic leukemia. Leukemia 8:2065–2075.

    PubMed  CAS  Google Scholar 

  43. Yang, G. S., Minden, M. D. and McCulloch, E. A. (1993). Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. Leukemia 7:1012–1019.

    PubMed  CAS  Google Scholar 

  44. Haldar, S., Jena, N. and Croce, C. M. (1995). Inactivation of bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA 92:4507–4511.

    Article  PubMed  CAS  Google Scholar 

  45. Haldar, S., Chintapalli, J. and Croce, C. M. (1996). Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1253–1255.

    PubMed  CAS  Google Scholar 

  46. Hu, Z.-B., Minden, M. D. and McCulloch, E. A. (1998). Phosphorylation of bcl-2 after exposure of human leukemic cells to retinoic acid. Blood 92:1768–1775.

    PubMed  CAS  Google Scholar 

  47. Dufour, P., Feugeas, O., Bergerat, J. P. and Oberling, F. (1994). Modulation of adriamicin cytotoxicity on K562 and K562adri cells by interferon alfa and/or all-trans-retinoic acid. Bull. Cancer 81:894–896.

    PubMed  CAS  Google Scholar 

  48. Akihiro, T., Takeshito, A., Shinjo, K., et al. (2000). Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukemia cells: analysis of intracellular concentration of ATRA. Br. J. Haematol 108:90–92.

    Article  Google Scholar 

  49. Ketley, N. J., Allen, P. D., Kelsey, S. M. and Newland, A. C. (2000). Mechanisms of resistance to apopitosis in human AML blasts. the role of differentiation-induced perturbations of cell-cycle checkpoints. Leukemia 14:620–628.

    Article  PubMed  CAS  Google Scholar 

  50. Andreeff, M., Jiang, S., Zhang, X., et al. (1999). Expression of bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 13:1881–1892.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Ankara University, School of Medicine, Sihhiye, Ankara, Turkey

    C. Üstün, M. Beksac (Professor of Medicine), K. Dalva, H. Koc, N. Konuk, O. Ilhan, M. Özcan & P. Topcuoglu

  2. Department of Statistics, Hacettepe University, Beytepe, Ankara, Turkey

    D. Sertkaya

  3. Department of Epidemiology, Hacettepe University, Medical School, Beytepe, Ankara, Turkey

    M. Hayran

Authors
  1. C. Üstün
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Beksac
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Dalva
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Koc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Konuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O. Ilhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Özcan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. Topcuoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D. Sertkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Hayran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Beksac.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Üstün, C., Beksac, M., Dalva, K. et al. In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia. Med Oncol 19, 59–67 (2002). https://doi.org/10.1385/MO:19:1:59

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:19:1:59

Key Words

Search

Navigation